- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer
-
- Takagi Mai
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Sagara Atsunobu
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Ishizawa Ayumi
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Ito Ayaka
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Miyazaki Masayuki
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Senzaki Kouji
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Nagai Taku
- Department of Hospital Pharmacy, Nagoya University Hospital
-
- Yamada Kiyofumi
- Department of Hospital Pharmacy, Nagoya University Hospital
Bibliographic Information
- Other Title
-
- 血清クレアチニン補正による腎機能評価が子宮頸がんシスプラチン+フルオロウラシル療法に与える影響
- ケッセイ クレアチニン ホセイ ニ ヨル ジンキノウ ヒョウカ ガ シキュウケイガン シスプラチン+フルオロウラシル リョウホウ ニ アタエル エイキョウ
Search this article
Description
<p>The dosage of cisplatin is adjusted according to creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula, which is commonly used as a marker for renal function. It is known that different serum creatinine (Scr) levels are reported depending on the analytical methods utilized such as the Scr level by the enzyme method being lower than that by the Jaffe method. Although the enzyme method is used in Japan, most drug dosages, including cisplatin, are adjusted according to the estimated Ccr using the Jaffe method-based Scr level. The purpose of this study was to investigate whether assessment of renal function with or without Scr adjustment affects cisplatin-based chemotherapy in cervical cancer patients. The patients were divided into two groups, normal (Ccr≥60 mL/min with adjusted Scr) and false normal (Ccr<60 mL/min with adjusted Scr, but Ccr≥60 mL/min with non-adjusted Scr). The false normal group had significantly higher rates of cisplatin dose reduction after the second course than the normal group (p<0.05). Leukocytopenia and Grade 2 or higher neutropenia were significantly more common in the false normal group than in the normal group (p<0.05). These results suggest that evaluation of renal function using the adjusted Scr is important for the accurate dosage of cisplatin and that it helps to improve the patient's quality of life. Further investigations may provide useful information for accurate and safe cisplatin-based chemotherapy for cancer patients.</p>
Journal
-
- YAKUGAKU ZASSHI
-
YAKUGAKU ZASSHI 139 (10), 1327-1332, 2019-10-01
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001277364095232
-
- NII Article ID
- 130007721875
-
- NII Book ID
- AN00284903
-
- ISSN
- 13475231
- 00316903
-
- NDL BIB ID
- 030023557
-
- PubMed
- 31582618
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed